{"id":4434,"date":"2026-11-18T18:03:00","date_gmt":"2026-11-18T22:03:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4434"},"modified":"2026-11-19T20:46:08","modified_gmt":"2026-11-20T00:46:08","slug":"fda-approves-c5-sirna-for-achr-positive-myasthenia","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4434","title":{"rendered":"FDA Approves C5 siRNA for AChR Positive Myasthenia"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Regeneron_Livsayis_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4439\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Regeneron_Livsayis_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Regeneron_Livsayis_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Regeneron_Livsayis_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Regeneron_Livsayis_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Regeneron_Livsayis_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Regeneron (siRNA platform licensed from Alnylam)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>FDA approval (prior-evening release recovered)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>siRNA<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Cemdisiran (Livsayis)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Complement C5 mRNA<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Anti-AChR-positive generalized myasthenia gravis<\/p>\n<h4>Summary<\/h4>\n<p>FDA approved cemdisiran, Livsayis, for adults with anti-AChR-positive generalized myasthenia gravis on November 18. The approval adds a quarterly subcutaneous C5-silencing option, with a boxed warning and REMS for meningococcal infection.<\/p>\n<p>Regeneron disclosed the decision at 6:03 p.m. EST November 18, inside this sweep\u2019s 36-hour window and after the prior evening\u2019s coverage. In Phase 3 NIMBLE, the company reports a 2.3-point placebo-adjusted improvement in MG-ADL at week 24 and a 2.8-point QMG difference. The approved label and prescribing information confirm indication and infection precautions. European review remains pending; no European approval occurred.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> infrequent dosing and validated functional improvement may reduce treatment burden in a crowded complement-inhibitor market.<\/p>\n<p><strong>Interpretation B:<\/strong> dosing convenience may be offset by access, payer restrictions, infection precautions or patient preference; cross-trial efficacy comparisons are unreliable. C5 suppression does not resolve all antibody-mediated disease biology. Longer-term persistence, rescue requirements, vaccination logistics and real-world adherence determine practical displacement. The siRNA platform is licensed from Alnylam; economics are not inferred from the approval.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Generalized myasthenia gravis is antibody-mediated neuromuscular-junction disease. Cemdisiran is an siRNA that degrades C5 mRNA in the liver, reducing circulating terminal-complement substrate.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Primary company release and product label verify action and data; efficacy figures are sponsor-reported trial results.<\/li>\n<li>Missing: comparative effectiveness, price and utilization.<\/li>\n<li>Upgrade: real-world disease control and access.<\/li>\n<li>Downgrade: breakthrough symptoms or safety burden.<\/li>\n<li>Falsifier for differentiation: no adherence or outcome advantage versus established C5 options.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a meaningful RNA-modality regulatory validation in neuromuscular disease, with commercial direction still unproven.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA approved cemdisiran, Livsayis, for adults with anti-AChR-positive generalized myasthenia gravis on November 18. The approval adds a quarterly subcutaneous C5-silencing option, with a boxed warning and REMS for meningococcal infection.<\/p>\n","protected":false},"author":1,"featured_media":4439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1554,860,121],"class_list":["post-4434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-cemdisiran","tag-myasthenia-gravis","tag-regeneron"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4434"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4434\/revisions"}],"predecessor-version":[{"id":4450,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4434\/revisions\/4450"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4439"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}